Monthly
US$200
Billed every month
Sign in to subscribeCrizotinib Capsules
Matched- Active ingredients (original)
- CRIZOTINIB
- Dosage form (original)
- CAPSULE
- Route (original)
- ORAL
Read these limits
- US patent expiration does not establish Chinese patent expiration. Dates here come from the US Orange Book; Chinese patent status needs separate checking.
- The Orange Book lists holder-submitted patents and does not cover all related patents.
- “Unmatched” means no English ingredient-name counterpart in the Chinese official-name sources loaded here; it does not mean no Chinese approval or filing. A zero count means a Chinese name is matched but no records were found in the loaded source. Source dates appear below.
- This page contains no sales or market-size data and cannot establish development value.
- Names on unmatched rows are the original FDA Orange Book names, without Chinese translation. The same ingredient may have a different generic name in China.
US-approved products
Application numbers, product numbers and original fields are retained. Marketing status is shown as listed in the source.
Earliest approval2011/08/26
ANDA applications0
RLD applicantPF PRISM CV
Currently marketed products: 2 · Counts FDA prescription and OTC marketing categories as listed; discontinued or unknown categories are excluded.
| Application / product number | Brand name (original) | Applicant (original) | Dosage form (original) | Route (original) | Strength (original) | Earliest approval | RLD / RS | Marketing status (original) | Official source |
|---|---|---|---|---|---|---|---|---|---|
| N202570-001 | XALKORI | PF PRISM CV | CAPSULE | ORAL | CRIZOTINIB: 200MG | 2011/08/26 | Y / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N202570-002 | XALKORI | PF PRISM CV | CAPSULE | ORAL | CRIZOTINIB: 250MG | 2011/08/26 | Y / Y | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
Listed US patents
*PED rows, substance/product flags, use codes and delisting-request flags are retained without determining legal effect.
Latest listed patent expiration2029/11/06
Substance patent expiration (DS flag)2029/11/06
This column includes only source rows explicitly flagged DS. A PED row without that flag is not assigned one by this site.
| Application / product number | Patent number | Listed expiration | Substance / product flags | Use code | Delisting request | Official source |
|---|---|---|---|---|---|---|
| N202570-001 | 7825137 | 2027/05/12 | — / — | U-3403 | — | openFDA ↗ |
| N202570-001 | 7858643 | 2029/10/08 | Y / Y | — | — | openFDA ↗ |
| N202570-001 | 8217057 | 2029/11/06 | Y / Y | — | — | openFDA ↗ |
| N202570-002 | 7825137 | 2027/05/12 | — / — | U-3403 | — | openFDA ↗ |
| N202570-002 | 7858643 | 2029/10/08 | Y / Y | — | — | openFDA ↗ |
| N202570-002 | 8217057 | 2029/11/06 | Y / Y | — | — | openFDA ↗ |
Exclusivity source records
FDA exclusivity code list ↗Latest exclusivity expiration: 2029/07/14
| Application / product number | Exclusivity code | Listed expiration | Official source |
|---|---|---|---|
| N202570-001 | ODE-328 | 2028/01/14 | openFDA ↗ |
| N202570-001 | ODE-407 | 2029/07/14 | openFDA ↗ |
| N202570-002 | ODE-328 | 2028/01/14 | openFDA ↗ |
| N202570-002 | ODE-407 | 2029/07/14 | openFDA ↗ |
Chinese record details
Chinese product landscape ↗The four-zero filter applies only to matched rows: catalog holders, NHSA approval numbers, applications under review, and companies filing generics this year. Unmatched rows have no Chinese counts. Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Catalog holders 3
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Kun Shan Long Deng Rui Di Pharmaceutical Co., Ltd. romanized | 国药准字H202632400.25g | 2026/01/27 | Official source ↗ |
| Kun Shan Long Deng Rui Di Pharmaceutical Co., Ltd. romanized | 国药准字H202632390.2g | 2026/01/27 | Official source ↗ |
| Jiangsu Wan Bang Sheng Hua Pharmaceuticals Group Co., Ltd. romanized | 国药准字H20234492200mg | 2023/11/21 | Official source ↗ |
| Jiangsu Wan Bang Sheng Hua Pharmaceuticals Group Co., Ltd. romanized | 国药准字H20234491250mg | 2023/11/21 | Official source ↗ |
| Pfizer Ltd. | H20171008;H20171011;H20171012200mg | 2013/01/22 | Official source ↗ |
| Pfizer Ltd. | H20171009;H20171013;H20171014250mg | 2013/01/22 | Official source ↗ |
NHSA approval numbers 3
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Chongqing Hua Sen Pharmaceutical Co., Ltd. romanized | 国药准字H202557020.25g | — | Official source ↗ |
| PFIZER EUROPE MA EEIG | 国药准字HJ20171011200mg | — | Official source ↗ |
| PFIZER EUROPE MA EEIG | 国药准字HJ20171011200mg | — | Official source ↗ |
| PFIZER EUROPE MA EEIG | 国药准字HJ20171013250mg | — | Official source ↗ |
| PFIZER EUROPE MA EEIG | 国药准字HJ20171013250mg | — | Official source ↗ |
Under review 7
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Kun Shan Long Deng Rui Di Pharmaceutical Co., Ltd. romanized | CYHB2600764 | 2026/04/16 | Official source ↗ |
| Kun Shan Long Deng Rui Di Pharmaceutical Co., Ltd. romanized | CYHB2600763 | 2026/04/16 | Official source ↗ |
| PFIZER EUROPE MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd. | JYHZ2600156 | 2026/06/30 | Official source ↗ |
| PFIZER EUROPE MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd. | JYHZ2600155 | 2026/06/30 | Official source ↗ |
| Chongqing Sheng Hua Xi Pharma Co., Ltd. romanized | CYHS2600730 | 2026/03/27 | Official source ↗ |
| Beijing Kang Li Sheng Pharmaceuticals Technology Kai Fa Co., Ltd. romanized; Jiangxi Shan Xiang Pharma Co., Ltd. romanized | CYHS2600661 | 2026/03/13 | Official source ↗ |
| Beijing Kang Li Sheng Pharmaceuticals Technology Kai Fa Co., Ltd. romanized; Jiangxi Shan Xiang Pharma Co., Ltd. romanized | CYHS2600660 | 2026/03/13 | Official source ↗ |
Generic-filing companies this year 2
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Chongqing Sheng Hua Xi Pharma Co., Ltd. romanized | CYHS2600730 | 2026/03/27 | Official source ↗ |
| Beijing Kang Li Sheng Pharmaceuticals Technology Kai Fa Co., Ltd. romanized; Jiangxi Shan Xiang Pharma Co., Ltd. romanized | CYHS2600661 | 2026/03/13 | Official source ↗ |
| Beijing Kang Li Sheng Pharmaceuticals Technology Kai Fa Co., Ltd. romanized; Jiangxi Shan Xiang Pharma Co., Ltd. romanized | CYHS2600660 | 2026/03/13 | Official source ↗ |
API companies with A status 3
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Chongqing Sheng Kai Pharmaceutical Co., Ltd. romanized | Y20230001144 | 2025/06/24 | Official source ↗ |
| MSN LABORATORIES PRIVATE LIMITED | Y20230001230 | 2026/01/16 | Official source ↗ |
| Xu Zhou Wan Bang Jin Qiao Pharmaceutical Co., Ltd. romanized | Y20210000680 | 2023/11/29 | Official source ↗ |
Trial registrations 2025/2026 —
Not loaded
Sources and dates
- FDA Orange Book
- 2026/11/06
- CDE acceptance and review
- 2026/11/13 06:42
- Chemical Drug Catalog
- 2026/11/13 06:39
- API registration records
- 2026/11/13 06:41
- NHSA drug code database
- 2026/10/23
- Trial registry
- 2026/11/13 08:09 · Incomplete coverage
Chinese counts use complete ingredient, dosage-form and route matches. Unmatched and partial rows show name-source matching only and make no finding about Chinese approvals or filings. Trials cover registration-number years 2025/2026 only.
Comparison generated: 2026/11/13 18:41 · openFDA Orange Book ↗
Name and dosage-form matching sources
- NMPA reference-product directory, Shaanxi MPA republication ↗ · 10-223 · 2021/06/28
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy